View Article

Abstract

Fluconazole is a triazole antifungal drug widely prescribed for systemic and mucocutaneous fungal infections. It acts by inhibiting fungal cytochrome P450-dependent 14?-demethylase, a key enzyme in ergosterol biosynthesis, leading to disruption of fungal cell membrane integrity. Due to its favorable pharmacokinetic profile, including high oral bioavailability and extensive tissue distribution, Fluconazole remains a first-line antifungal therapy. The accurate determination of Fluconazole in pharmaceutical formulations and biological matrices is critical for quality control, pharmacokinetic, and therapeutic drug monitoring purposes. This review highlights the physicochemical properties, pharmacological profile, and a comprehensive overview of analytical techniques employed for its quantification—such as spectrophotometry, HPLC, LC–MS/MS, GC, CE, and electrochemical methods. Each technique is discussed with respect to its principle, analytical performance, sample preparation, advantages, and limitations. Furthermore, recent advancements in miniaturized and high-sensitivity detection systems are emphasized.

Keywords

Fluconazole, Triazole antifungal, HPLC, LC–MS/MS, Spectrophotometry, Analytical methods, Drug quantification, Method validation

Introduction

Fungal infections have become a significant global health concern, particularly among immunocompromised individuals such as those undergoing chemotherapy, organ transplantation, or living with conditions like HIV/AIDS. Fungi, although a normal part of the human microbiota, can cause opportunistic infections when the immune system is weakened or compromised. The most common fungal pathogens include Candida spp., Aspergillus spp., Cryptococcus neoformans, and Histoplasma capsulatum. These infections range from superficial, affecting the skin, nails, and mucous membranes, to invasive systemic infections that can be life-threatening. The clinical significance of antifungal agents cannot be overstated. Effective antifungal therapy reduces morbidity and mortality in vulnerable populations, prevents the spread of fungal pathogens, and complements other treatment regimens such as antibiotics and immunosuppressive therapies. However, challenges such as drug interactions, toxicity, and resistance demand continuous research and development in antifungal pharmacology, therapeutic monitoring, and analytical methodologies. Fluconazole, a second-generation triazole antifungal agent, was first synthesized in the late 1970s and introduced into clinical practice in the early 1990s. It was developed as an improvement over earlier azoles like ketoconazole, offering better oral bioavailability, broader antifungal spectrum, and fewer adverse effects. The drug’s success lies in its unique chemical structure—a fluorinated derivative of the azole ring—which enhances its water solubility and systemic distribution. Therapeutically, fluconazole is widely used to treat fungal infections caused by susceptible organisms. It is effective against various Candida species, including Candida albicans, C. glabrata (with caution), C. parapsilosis, and C. tropicalis, making it a first-line treatment for oropharyngeal candidiasis, esophageal candidiasis, vaginal candidiasis, and systemic candidemia. It is also employed in the treatment and prevention of cryptococcal meningitis, particularly in HIV/AIDS patients, and in the management of fungal infections in immunocompromised hosts. The spectrum of activity of fluconazole is primarily fungistatic rather than fungicidal, meaning it inhibits fungal growth without directly killing the cells. Nevertheless, its favorable safety profile, oral administration, and extensive tissue penetration— including cerebrospinal fluid—have made it indispensable in both acute and long-term antifungal therapy. Despite its advantages, fluconazole’s use must be carefully monitored due to emerging resistance patterns and potential interactions with other drugs metabolized by cytochrome P450 enzymes. The objective of this review is to comprehensively explore the physicochemical properties and analytical methods employed for the determination of fluconazole. Given its extensive therapeutic application, ensuring the quality, safety, and efficacy of fluconazole through accurate and precise analytical techniques is of paramount importance. Understanding the physicochemical properties of fluconazole is essential because these characteristics directly impact its formulation, delivery, stability, and therapeutic action. Properties such as solubility, partition coefficient, melting point, and pKa determine how fluconazole behaves in different environments—whether in the gastrointestinal tract, bloodstream, or targeted tissues. For instance, its high aqueous solubility facilitates oral absorption, while its moderate lipophilicity enables effective distribution across biological membranes. Analytical determination of fluconazole is equally vital in ensuring therapeutic success. Precise quantification techniques are required at multiple stages—from raw material testing to finished product release and post-marketing surveillance. In clinical settings, therapeutic drug monitoring is necessary to avoid toxicity, especially in populations with compromised liver or kidney function. Analytical methods help detect variations in drug concentration, assess pharmacokinetic parameters, and guide dose adjustments. In summary, a deep understanding of fluconazole’s properties and analytical determination not only enhances drug development and clinical management but also safeguards patient health and contributes to global efforts against antifungal resistance.

AIM:

The aim of this review is to provide a comprehensive overview of the physicochemical properties of fluconazole and the various analytical methods used for its determination.

OBJECTIVES:

  1. To describe the chemical, physical, and pharmacokinetic properties of fluconazole
  2. To summarize the mechanisms of action and clinical relevance of fluconazole
  3. To review the analytical methods used for fluconazole determination
  4. To assess the role of analytical methods in pharmaceutical quality control and therapeutic drug monitoring
  5. To identify challenges and areas for improvement in fluconazole analysis
  6. To provide insights into future trends and research directions

Analytical Methods for Determination of Fluconazole:

Reference

  1. Playford EG, Webster AC, Sorell TC, Craig JC. Antifungal agents for preventing fungal infections in solid organ transplant recipients.                                                                                                       
  2. The Cochrane Database of Systematic Reviews 2004;(Issue 3). doi:10.1002/14651858. Art. No. CD004291.pub2.
  3. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic crit-ically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother 2006; 57:628e38.
  4. Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment. The Cochrane Database of Systematic Reviews 2004;(Issue 4). doi:10.1002/14651858. Art. No. CD003807.pub2.
  5. Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. The Cochrane Database of Systematic Reviews 2002; (Issue 2). doi:10.1002/14651858. Art. No. CD000026.
  6. McGuire W, Clerihew L, Austin N. Prophylactic intravenous anti-fungal agents to prevent mortality and morbidity in very low birth weight infants. The Cochrane Database of Systematic Reviews 2004;(Issue 1). doi:10.1002/14651858. Art. No. CD003850.pub2.
  7. Charlier C, Hart E, Lefort A, Ribaud P, Dromer F, Denning DW, et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 2006; 57:384e410.
  8. Kaufman D, Gurka MJ, Boyle R, Grossman LB. Fluconazole pro-phylaxis in preterm infants: meta-analysis of controlled stud-ies. E-PAS 2006; 59:2540e4, available at http://www.aps-spr.
  9. Novelli V, Holzel H. Safety and tolerability of fluconazole in children. Antimicrob Agents Chemother 1999; 43:1955e60.
  10. Frattarelli DAC, Reed MD, Giacoia GP, Aranda JV. Antifungals in systemic neonatal candidiasis. Drugs 2004; 64:949e68.

Photo
Dnyaneshwari Gaikwad
Corresponding author

B. Pharmacy, S.N.D College of Pharmacy, Babhulgaon

Photo
Amol Gayke
Co-author

B. Pharmacy, S.N.D College of Pharmacy, Babhulgaon

Photo
Amol Jadhav
Co-author

B. Pharmacy, S.N.D College of Pharmacy, Babhulgaon

Photo
Komal Kute
Co-author

B. Pharmacy, S.N.D College of Pharmacy, Babhulgaon

Dnyaneshwari Gaikwad*, Amol Gayke, Amol Jadhav, Komal Kute, Review on Fluconazole: Properties and Analytical Methods for its Determination, Int. J. Sci. R. Tech., 2025, 2 (11), 582-586. https://doi.org/10.5281/zenodo.17667963

More related articles
Formulation and Evaluation of Dexlansoprazole-Load...
Aashwini Ghuge , Dr. Pravin Wakte, Dr. Sachin Bhusari , Renuka Dh...
Social Media: Building Connections or Breaking Bon...
Dr. Abhishek Kumar Singh, Divyanshi Rathour, ...
Aphaisia: A Comprehensive Language Disorder, Clini...
Pooja Rasal, Granthali Shape, Poonam Yadav, ...
Related Articles
Herbal Fusion: A Novel Skin Brightening Face Pack form Natural Sources...
Nayan Anil Sardar , Shivaji Katade, Ram Baban Ingle, ...
Pharmacists as Guardians of Patient Safety: A Review of Their Critical Role in M...
Arnab Roy, Indrajeet Kumar Mahto, Anupama Kumari, Raj Kumar, Warisha Sami, Chandan Kumar, Ayush Kuma...
Formulation and Evaluation of Dexlansoprazole-Loaded Solid Lipid Nanoparticles f...
Aashwini Ghuge , Dr. Pravin Wakte, Dr. Sachin Bhusari , Renuka Dhakne, Dr. Preeti Sable , ...
More related articles
Formulation and Evaluation of Dexlansoprazole-Loaded Solid Lipid Nanoparticles f...
Aashwini Ghuge , Dr. Pravin Wakte, Dr. Sachin Bhusari , Renuka Dhakne, Dr. Preeti Sable , ...
Social Media: Building Connections or Breaking Bonds?...
Dr. Abhishek Kumar Singh, Divyanshi Rathour, ...
Formulation and Evaluation of Dexlansoprazole-Loaded Solid Lipid Nanoparticles f...
Aashwini Ghuge , Dr. Pravin Wakte, Dr. Sachin Bhusari , Renuka Dhakne, Dr. Preeti Sable , ...
Social Media: Building Connections or Breaking Bonds?...
Dr. Abhishek Kumar Singh, Divyanshi Rathour, ...